[Use of recombinant alpha2-interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia].

IF 0.2 4区医学 Q4 HEMATOLOGY

Gematologiya I Transfuziologiya Pub Date : 1996-01-01

V I Petukhov, I Strozha, D K Bondare, G Ia Feldmane, M Mauritsas

引用次数: 0

Abstract

The authors present results of chronic myeloid leukemia (CML) treatment with recombinant and leukocytic interferon in monotherapy and in combination with myelosan. The best responses (72% of complete hematological remissions) were obtained in patients pretreated with myelosan (one course of 1-1.5 months) in combination with natural antioxidants.

本刊更多论文

[重组α 2-干扰素联合髓糖治疗慢性髓系白血病]。

作者报告了重组干扰素和白细胞干扰素单药治疗和与髓糖联合治疗慢性髓性白血病(CML)的结果。髓聚糖(1-1.5个月一个疗程)与天然抗氧化剂联合治疗的患者获得最佳疗效(72%的血液学完全缓解)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gematologiya I Transfuziologiya 医学-血液学

CiteScore

0.80

自引率

66.70%

发文量

审稿时长

>12 weeks

期刊介绍： The journal publishes original theoretical and clinical studies, lectures, reviews, and practical notes concerning various problems of hematology and clinical and industrial transfusion. The journal provides information on the etiology, pathogenesis, diagnosis and treatment of blood disorders as well as on related non-hematological conditions (internal diseases, poisoning, exposure to ionizing radiation etc.).